The glucagon-receptor activity is the part that makes retatrutide pharmacologically distinct
This, combined with the drug shortages and increasing public attention, has prompted an FDA warning about the risks of obtaining compounded versions of semaglutide which may contain untested versions of the drug or other inappropriate additives [13]
Both are formulated to assist in weight loss and blood sugar control
15 Dahl, D., et al., Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial
For semaglutide users, best means: high-protein, low-irritation, and easy to tolerate when gastric emptying is slowed
Food and Drug Administration (FDA) have not approved retatrutide yet